News

Expanding on our existing ADCC product line, presenting new iLite ADCC Target HER2 Assay Ready Cells

April 26, 2017 - Company News, Product News
The iLite ADCC HER2 Assay Ready Cells build on and expand the unique ADCC assay system launched in 2016, including target positive and negative cells for use with the iLite ADCC Effector Assay Ready Cells.

Therapeutic antibodies are increasingly used to treat different types of cancer, including breast cancer, the second most commonly diagnosed cancer worldwide. The activity of a number of therapeutic antibodies is mediated at least in part by antibody dependent cell-mediated cytotoxicity (ADCC), including trastuzumab, an anti-HER2 antibody commonly used for treating HER2 positive breast cancer patients.
 
The iLite ADCC HER2 Assay Ready Cells are genetically engineered cell lines, optimized and matched for use with the iLite ADCC Effector Assay Ready Cells. This unique setup for running an anti-HER2 ADCC activity assay combines high sensitivity and specificity, can be run within one workday and does not require any cell culturing.

To learn more about the iLite ADCC Target HER2 Assay Ready Cells, click here.

 

« Back